Skip to main content
Caplight Logo









Flindr Therapeutics

Flindr Therapeutics

Private
OssHealthcare & Life Scienceshttps://flindrtx.com/

Last Round

Series A

Apr 24, 2024

Total Funding Raised

$21.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Flindr Therapeutics is a biotechnology company developing a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

small molecule inhibitorsprecision oncologyfirst-in-class therapiesRNF31 inhibitortarget discoverydrug discovery enginepre-clinical biotechE3 ubiquitin ligasedrug licensingreverse translationHOIP inhibitorB-cell lymphoma treatmentovarian cancer treatmentAI-enabled drug discoveryIND applicationstructure-based drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flindr Therapeutics Comparables

Compare Flindr Therapeutics with similar companies based on industry and business-model similarity.

Flindr Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Outrun Therapeutics
84%
Eisbach Bio GmbH
78%
Light Horse Therapeutics
77%

Flindr Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 24, 2024

Key People

Founding team and executive leadership

Maarten Ligtenberg

Chief Executive Officer at Flindr Therapeutics

Executive Team

Flindr Therapeutics Investors

Notable investors and investment history

Flindr Therapeutics investors
InvestorRounds
Brabantse Ontwikkelings MaatschappijSeed, Series A
Swanbridge CapitalSeed, Series A
Innovatiefonds Noord-HollandSeed
V-Bio VenturesSeries A
Oncode InstituteSeed, Series A
PMVSeries A
Johnson & Johnson Innovation - JJDC, Inc.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Grew 17% QoQ from 18 to 21 employees.

  • Jan 24, 2026

    Monthly visitors increased 505% MoM, from 74 to 448.

Flindr Therapeutics Filings

Explore SEC and related filing metadata, where available.

Flindr Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Flindr Therapeutics's valuation, stock price, and market status.

Is Flindr Therapeutics a public or private company?

Flindr Therapeutics is a private company.

What is the current stock price of Flindr Therapeutics?

Flindr Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Flindr Therapeutics worth (valuation)?

Valuation information for Flindr Therapeutics is not publicly available.

Can I buy Flindr Therapeutics stock?

Flindr Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Flindr Therapeutics's last funding round?

Flindr Therapeutics's most recent funding round was Series A on April 24, 2024.

Who are the main investors in Flindr Therapeutics?

Key investors in Flindr Therapeutics include V-Bio Ventures.

Will Flindr Therapeutics IPO soon?

No public IPO plans have been announced for Flindr Therapeutics.

How can I track Flindr Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Flindr Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOss
Employee Range16
Year Founded2020
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?